Mereo BioPharma Faces Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy MREO?
Source: Globenewswire
- Lawsuit Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Mereo BioPharma Group plc for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025.
- False Statements: The complaint alleges that Mereo concealed negative facts regarding its Phase 3 ORBIT and COSMIC programs, rendering its public statements throughout the class period false and materially misleading.
- Investor Losses: When the market learned that Mereo failed to meet its primary endpoints, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact future stock performance.
- Join the Lawsuit: Affected shareholders are encouraged to contact the Schall Law Firm before April 6, 2026, to participate in the lawsuit and seek compensation, highlighting the potential legal risks the company faces regarding compliance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MREO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MREO
Wall Street analysts forecast MREO stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.391
Low
0.50
Averages
2.08
High
5.00
Current: 0.391
Low
0.50
Averages
2.08
High
5.00
About MREO
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Filed Against Mereo BioPharma Group for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Mereo BioPharma Group, seeking damages for investors who purchased securities between June 5, 2023, and December 26, 2025, reflecting strong investor response to potential fraud allegations.
- Allegations of False Statements: The complaint alleges that Mereo provided overly positive statements to investors while concealing significant adverse facts regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints, potentially undermining investor confidence.
- Call to Action for Investors: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, to share in any potential recovery from the lawsuit, indicating the legal team's commitment to protecting investor rights.
- No-Cost Legal Services: The law firm offers legal representation on a contingency fee basis, meaning they will only charge fees if they successfully recover funds, thereby reducing the legal risk for investors and enhancing the appeal of participating in the lawsuit.
See More
Mereo BioPharma Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Mereo BioPharma Group plc for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025.
- False Statements Exposed: The complaint alleges that Mereo concealed negative facts about its Phase 3 ORBIT and COSMIC programs, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: When the market learned that Mereo failed to meet its primary endpoints, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact future stock performance.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected investors to contact them before April 6, 2026, to participate in the lawsuit and discuss their rights, demonstrating a commitment to protecting investor interests.
See More
Faruqi & Faruqi Encourages Mereo Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Mereo BioPharma, specifically targeting investors who purchased or acquired securities between June 5, 2023, and December 26, 2025, to protect their legal rights.
- Class Action Reminder: The firm reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against Mereo, urging timely action to safeguard their interests.
- Direct Contact Channels: Investors who suffered losses are encouraged to reach out directly to Faruqi & Faruqi's Securities Litigation Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for consultation.
- Investor Rights Protection: This legal action aims to support affected investors and ensure they receive due compensation in potential securities fraud cases, reflecting the firm's commitment to protecting investor rights.
See More
Reminder of Class Action for Mereo BioPharma ADS Purchasers
- Class Action Notice: Rosen Law Firm reminds investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided false and misleading information regarding the Phase 3 Orbit and COSMIC studies, claiming setrusumab would significantly reduce annualized fracture rates, while these studies failed to meet primary endpoints, causing investors to buy ADS at inflated prices.
- Legal Counsel Recommendation: Investors are encouraged to select law firms with proven success; Rosen Law Firm has a strong track record in securities class actions, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and resources in this field.
- Investor Rights Protection: Until the class action is certified, investors can choose to retain counsel or remain absent, with their ability to share in any potential future recovery not dependent on serving as lead plaintiff, ensuring their rights are adequately protected.
See More
Reminder of Class Action for Mereo BioPharma Investors
- Class Action Notification: Rosen Law Firm reminds investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors can join the lawsuit through a contingency fee arrangement, meaning they will not incur any upfront costs, thereby reducing the financial burden of participation.
- Lawsuit Background: The lawsuit alleges that Mereo BioPharma's positive statements regarding setrusumab in its Phase 3 Orbit and COSMIC studies contradicted the reality of failing to meet primary endpoints, leading investors to purchase ADS at inflated prices and suffer losses.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Class Action Reminder for Mereo BioPharma Shareholders
- Lawsuit Background: Robbins LLP reminds all investors who purchased Mereo BioPharma Group plc (NASDAQ: MREO) American Depository Shares between June 5, 2023, and December 26, 2025, that a class action has been filed, alleging the company misled investors regarding the results of its drug studies.
- Study Failures: The complaint highlights that Mereo's Phase 3 ORBIT and COSMIC studies for Osteogenesis Imperfecta failed to meet their primary endpoint of reducing annualized fracture rates, despite the company's prior confidence, leading investors to buy shares at artificially inflated prices.
- Stock Price Plunge: On December 29, 2025, Mereo announced that its studies did not meet expectations, causing the stock price to plummet from $2.31 per share on December 26, 2025, to $0.29 per share, a decline of over 87.7%, severely impacting shareholder value.
- Opportunity to Participate: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 6, 2026, indicating the importance of corporate governance and shareholder rights in the wake of such significant losses.
See More
Class Action Filed Against Mereo BioPharma Group for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Mereo BioPharma Group, seeking damages for investors who purchased securities between June 5, 2023, and December 26, 2025, reflecting strong investor response to potential fraud allegations.
- Allegations of False Statements: The complaint alleges that Mereo provided overly positive statements to investors while concealing significant adverse facts regarding the Phase 3 ORBIT and COSMIC programs, which failed to meet their primary endpoints, potentially undermining investor confidence.
- Call to Action for Investors: Affected investors are encouraged to apply to be lead plaintiffs by April 6, 2026, to share in any potential recovery from the lawsuit, indicating the legal team's commitment to protecting investor rights.
- No-Cost Legal Services: The law firm offers legal representation on a contingency fee basis, meaning they will only charge fees if they successfully recover funds, thereby reducing the legal risk for investors and enhancing the appeal of participating in the lawsuit.
See More
Mereo BioPharma Faces Class Action Lawsuit
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Mereo BioPharma Group plc for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025.
- False Statements Exposed: The complaint alleges that Mereo concealed negative facts about its Phase 3 ORBIT and COSMIC programs, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: When the market learned that Mereo failed to meet its primary endpoints, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact future stock performance.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected investors to contact them before April 6, 2026, to participate in the lawsuit and discuss their rights, demonstrating a commitment to protecting investor interests.
See More
Faruqi & Faruqi Encourages Mereo Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Mereo BioPharma, specifically targeting investors who purchased or acquired securities between June 5, 2023, and December 26, 2025, to protect their legal rights.
- Class Action Reminder: The firm reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against Mereo, urging timely action to safeguard their interests.
- Direct Contact Channels: Investors who suffered losses are encouraged to reach out directly to Faruqi & Faruqi's Securities Litigation Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for consultation.
- Investor Rights Protection: This legal action aims to support affected investors and ensure they receive due compensation in potential securities fraud cases, reflecting the firm's commitment to protecting investor rights.
See More
Reminder of Class Action for Mereo BioPharma ADS Purchasers
- Class Action Notice: Rosen Law Firm reminds investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided false and misleading information regarding the Phase 3 Orbit and COSMIC studies, claiming setrusumab would significantly reduce annualized fracture rates, while these studies failed to meet primary endpoints, causing investors to buy ADS at inflated prices.
- Legal Counsel Recommendation: Investors are encouraged to select law firms with proven success; Rosen Law Firm has a strong track record in securities class actions, recovering over $438 million for investors in 2019 alone, demonstrating its expertise and resources in this field.
- Investor Rights Protection: Until the class action is certified, investors can choose to retain counsel or remain absent, with their ability to share in any potential future recovery not dependent on serving as lead plaintiff, ensuring their rights are adequately protected.
See More
Reminder of Class Action for Mereo BioPharma Investors
- Class Action Notification: Rosen Law Firm reminds investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors can join the lawsuit through a contingency fee arrangement, meaning they will not incur any upfront costs, thereby reducing the financial burden of participation.
- Lawsuit Background: The lawsuit alleges that Mereo BioPharma's positive statements regarding setrusumab in its Phase 3 Orbit and COSMIC studies contradicted the reality of failing to meet primary endpoints, leading investors to purchase ADS at inflated prices and suffer losses.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Class Action Reminder for Mereo BioPharma Shareholders
- Lawsuit Background: Robbins LLP reminds all investors who purchased Mereo BioPharma Group plc (NASDAQ: MREO) American Depository Shares between June 5, 2023, and December 26, 2025, that a class action has been filed, alleging the company misled investors regarding the results of its drug studies.
- Study Failures: The complaint highlights that Mereo's Phase 3 ORBIT and COSMIC studies for Osteogenesis Imperfecta failed to meet their primary endpoint of reducing annualized fracture rates, despite the company's prior confidence, leading investors to buy shares at artificially inflated prices.
- Stock Price Plunge: On December 29, 2025, Mereo announced that its studies did not meet expectations, causing the stock price to plummet from $2.31 per share on December 26, 2025, to $0.29 per share, a decline of over 87.7%, severely impacting shareholder value.
- Opportunity to Participate: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 6, 2026, indicating the importance of corporate governance and shareholder rights in the wake of such significant losses.
See More
